Literature DB >> 12160959

Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts.

Marie Joyeux1, Claire Arnaud, Diane Godin-Ribuot, Pierre Demenge, Daniel Lamontagne, Christophe Ribuot.   

Abstract

OBJECTIVE: We have investigated the involvement of the endocannabinoid system in the delayed cardioprotection conferred by heat stress preconditioning in the isolated rat heart.
METHODS: Rats were divided into eight groups (n=7 in each group), subjected to either heat stress (42 degrees C for 15 min, HS groups) or sham anaesthesia (Sham groups). Twenty-four hours later, their hearts were isolated, retrogradely perfused, and subjected to a 30-min occlusion of the left coronary artery followed by 120 min of reperfusion. Some hearts were perfused with either SR 141716 (a cannabinoid CB(1) receptor antagonist, 1 microM), SR 144528 (a CB(2) receptor antagonist, 1 microM) or L-NAME (a NOS inhibitor, 3 microM) 5 min before ischaemia and during the ischaemic period.
RESULTS: The infarct size-reducing effect conferred by heat stress (35.7+/-1.8% in Sham to 14.1+/-0.6% in HS groups) was not altered by the perfusion of SR 141716 (11.2+/-1.5%) but was abolished by both SR 144528 (36.6+/-1.6%) and L-NAME (32.0+/-4.4%). In hearts from non-heat-stressed rats, perfusion with SR 141716 (32.8+/-1.6%), SR 144528 (33.4+/-2.2%) and L-NAME (31.6+/-2.9%) had no effect on infarct size.
CONCLUSION: These results suggest an involvement of endocannabinoids, acting through CB(2) receptors, and NO in the cardioprotection conferred by heat stress against myocardial ischaemia. The possible interaction between both mediators of the heat stress response remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12160959     DOI: 10.1016/s0008-6363(02)00268-7

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  20 in total

1.  Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator.

Authors:  X Zhang; Y Maor; J F Wang; G Kunos; J E Groopman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism.

Authors:  Nichola J Underdown; C Robin Hiley; William R Ford
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

Review 3.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

Review 4.  The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2.

Authors:  Makenzie L Fulmer; Douglas P Thewke
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2018

5.  Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies.

Authors:  Sabine Steffens; Pál Pacher
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 6.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 7.  The emerging role of the endocannabinoid system in cardiovascular disease.

Authors:  Pál Pacher; Sabine Steffens
Journal:  Semin Immunopathol       Date:  2009-04-09       Impact factor: 9.623

Review 8.  Endocannabinoids and the heart.

Authors:  C Robin Hiley
Journal:  J Cardiovasc Pharmacol       Date:  2009-04       Impact factor: 3.105

9.  Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.

Authors:  V E Mendizábal; E Adler-Graschinsky
Journal:  Br J Pharmacol       Date:  2007-04-23       Impact factor: 8.739

Review 10.  Cannabinoid receptors in acute and chronic complications of atherosclerosis.

Authors:  F Mach; F Montecucco; S Steffens
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.